Pricing Log in Create free account

Immunome, Inc. (IMNM) vs Pharvaris N.V. (PHVS)

Immunome, Inc. and Pharvaris N.V. are both Biotechnology companies. Immunome, Inc. and Pharvaris N.V. are of similar size ($2.3B and $2.1B). Across the 11 metrics below, Immunome, Inc. leads on 7 and Pharvaris N.V. on 4.

Valuation

Metric IMNM PHVS Biotechnology median
P/E n/m n/m 10.26
P/S 162.50 n/m 9.18
P/B 3.90 6.38 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 121.23 n/m 8.98
Earnings yield (14.01%) (9.30%) (34.89%)
Free cash flow yield (10.71%) (7.98%) (24.52%)

Profitability

Metric IMNM PHVS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.03%) (71.50%) (50.12%)
Return on assets (59.03%) (64.43%) (45.60%)
Return on invested capital (3,322.99%) 0.00% 0.00%

Growth

Metric IMNM PHVS Biotechnology median
Revenue growth (TTM) 16.74% — 6.26%
EPS growth (last fiscal year) 51.40% (25.37%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMNM PHVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.08 11.94 4.89
Net debt to EBITDA 2.92 1.72 1.01

Dividend

Metric IMNM PHVS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMNM PHVS Biotechnology median
Market cap 2.11b 2.28b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack